Table 2.

Efficacy of delayed therapy against a disseminatedC. albicans MY1055 infection in the CY-induced, transient-suppression model in ICR micea

Dose (mg/kg)Mean log10 CFU/g of kidneys (% sterilization)b
CaspofungincAmBd
2.02.10*f ± 0.01 (100)NTe
1.02.14* ± 0.04 (100)2.89* ± 0.63 (20)
0.52.13* ± 0.05 (100)3.48* ± 0.62 (0)
0.252.38* ± 0.58 (80)4.46* ± 0.99 (0)
0.1254.62* ± 0.80 (0)4.78* ± 0.92 (0)
0.0636.06 ± 0.57 (0)5.61* ± 0.69 (0)
06.47 ± 0.12 (0)6.47 ± 0.12 (0)
  • a Mice were challenged i.v. with C. albicans MY1055 at 2.0 × 104 CFU/mouse. Mice received first treatment 24 h after challenge (delayed therapy) and were treated i.p., q.d., for 7 days. Kidneys were aseptically collected at day 8 after challenge.

  • b Mean log10 CFU/gram ± standard deviation at 8 days after challenge for paired kidneys. There were five mice per group except for the groups receiving no drug (three mice per group). Percent sterilization indicates the number of mice with no detectable yeast, where the limit of detection was 50 yeast cells per pair of kidneys.

  • c ED90s and ED99s (95% confidence intervals) were calculated based on reduction in CFU/gram of kidneys of treated groups compared to sham-treated control animals and were 0.049 (0.014, 0.180) and 0.119 (0.038, 0.374), respectively.

  • d See footnote c. Corresponding values were 0.071 (0.020, 0.254) and 0.198 (0.069, 0.571), respectively.

  • e NT, not tested.

  • f *, significantly different from result for sham-treated control (P < 0.05; Excel ttest).